LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

30.03.2022 - Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM ...

Related Keywords

China ,Hainan Province ,Hainan ,Shanghai ,Chinese ,Susan Silbermann ,Jesse Wu ,Michael Humphries ,Bristol Myers Squibb ,Yizhe Wang ,Drug Administration ,Products Administration Of Hainan Province ,Exchange Commission ,Clinical Development Updates ,Research Development Expenses ,National Medical Products Administration ,Boao Lecheng International Medical Tourism Pilot Zone ,Health Commission ,Patient Program ,Chief Executive ,Greater China ,Business Highlights ,Clinical Development ,Drug Evaluation ,Breakthrough Therapy ,Medical Products Administration ,Named Patient Program ,Chief Scientific Advisor ,Anticipated Milestones Expected ,Prescription Drug User Fee Act ,New Drug Application ,Redeemable Convertible Preferred Shares ,Shareholder Equity ,